KZIA20261120P20
KZIA Nov 20 2026 20.00 Put (KZIA261120P00020000)
option OPRA

innovative. focused. agile. kazia therapeutics is an agile, oncology-focused biotechnology company, based in sydney, australia. we have two clinical staged drug development candidates and an early stage discovery program, across a range of oncology indications. our lead program is gdc-0084, a small molecule inhibitor of the pi3k / akt / mtor pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. licensed from genentech in late 2016, gdc-0084 is anticipated to enter phase ii clinical trials in 2017. trxe-002-1, or cantrixil is kazia's second drug development candidate under development as a treatment for ovarian cancer. the chemotherapeutic is currently undergoing a phase 1 clinical trial in hospitals across australia and the united states. initial data on this trial is expected to be reported early in 2018. kazia therapeutics is trading under the following tickers: asx: kza nasdaq: kzia for more information, please visi